{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:19Z","timestamp":1790286919992,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03193-3","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T02:30:04Z","timestamp":1765506604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug-induced cutaneous toxicities in solid tumor oncology: mechanisms, manifestations, and management"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-2359","authenticated-orcid":false,"given":"Vladislav","family":"Skossyrskiy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8468-2106","authenticated-orcid":false,"given":"Maxim","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-4179","authenticated-orcid":false,"given":"Igor","family":"Gadaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-7094","authenticated-orcid":false,"given":"Marina","family":"Sekacheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-8781","authenticated-orcid":false,"given":"Ekaterina","family":"Orlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"3193_CR1","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. National Cancer Institute; 2017.\u00a0https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"3193_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","volume":"16","author":"C Pinto","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with Cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist. 2011;16:228\u201338. https:\/\/doi.org\/10.1634\/theoncologist.2010-0298.","journal-title":"Oncologist"},{"key":"3193_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.18821\/1560-9588-2016-19-3-136-140","volume":"19","author":"EA Shatokhina","year":"2016","unstructured":"Shatokhina EA, Kotenko KV, Kruglova LS. Cutaneous toxic effects of targeted therapy: clinical manifestations and correction. Ross Zh Kozhn Ven Bol. 2016;19:136\u201340. https:\/\/doi.org\/10.18821\/1560-9588-2016-19-3-136-140.","journal-title":"Ross Zh Kozhn Ven Bol"},{"key":"3193_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20:815\u201334. https:\/\/doi.org\/10.2174\/1568026620666200303123102.","journal-title":"Curr Top Med Chem"},{"key":"3193_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/03008916211005546","volume":"108","author":"D Zhao","year":"2022","unstructured":"Zhao D, Fan J, Peng L, et al. Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement. Tumori. 2022;108:12\u20138. https:\/\/doi.org\/10.1177\/03008916211005546.","journal-title":"Tumori"},{"key":"3193_CR6","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","volume":"37","author":"Z An","year":"2018","unstructured":"An Z, Aksoy O, Zheng T, et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561\u201375. https:\/\/doi.org\/10.1038\/s41388-017-0045-7.","journal-title":"Oncogene"},{"key":"3193_CR7","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/ijms23073818","volume":"23","author":"S Nair","year":"2022","unstructured":"Nair S, Bonner JA, Bredel M. EGFR mutations in head and neck squamous cell carcinoma. Int J Mol Sci. 2022;23:3818. https:\/\/doi.org\/10.3390\/ijms23073818.","journal-title":"Int J Mol Sci"},{"key":"3193_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jss.2011.04.041","volume":"173","author":"A Chernoguz","year":"2012","unstructured":"Chernoguz A, Crawford K, Donovan E, et al. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing\u2019s sarcoma model. J Surg Res. 2012;173:1\u20139. https:\/\/doi.org\/10.1016\/j.jss.2011.04.041.","journal-title":"J Surg Res"},{"key":"3193_CR9","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33:466\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.003.","journal-title":"Ann Oncol"},{"key":"3193_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"key":"3193_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1634\/theoncologist.10-5-345","volume":"10","author":"R P\u00e9rez-Soler","year":"2005","unstructured":"P\u00e9rez-Soler R, Delord JP, Halpern A, et al. HER1\/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1\/EGFR inhibitor rash management forum. Oncologist. 2005;10:345\u201356. https:\/\/doi.org\/10.1634\/theoncologist.10-5-345.","journal-title":"Oncologist"},{"key":"3193_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jfma.2017.03.001","volume":"116","author":"C-Y Chu","year":"2017","unstructured":"Chu C-Y, Chen K-Y, Wen-Cheng Chang J, et al. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc. 2017;116:413\u201323. https:\/\/doi.org\/10.1016\/j.jfma.2017.03.001.","journal-title":"J Formos Med Assoc"},{"key":"3193_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1283807","author":"H Dan","year":"2024","unstructured":"Dan H, Jiang Q, Jia X, et al. Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023. Front Med. 2024. https:\/\/doi.org\/10.3389\/fmed.2023.1283807.","journal-title":"Front Med"},{"key":"3193_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12885-020-07685-5","volume":"21","author":"N Joly-Tonetti","year":"2021","unstructured":"Joly-Tonetti N, Ondet T, Monshouwer M, Stamatas GN. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer. 2021;21:5. https:\/\/doi.org\/10.1186\/s12885-020-07685-5.","journal-title":"BMC Cancer"},{"key":"3193_CR15","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00520-016-3419-4","volume":"25","author":"B Tischer","year":"2017","unstructured":"Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25:651\u201360. https:\/\/doi.org\/10.1007\/s00520-016-3419-4.","journal-title":"Support Care Cancer"},{"key":"3193_CR16","first-page":"1","volume":"63","author":"C Kari","year":"2003","unstructured":"Kari C, Chan TO, Rocha de Quadros M, Rodeck U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003;63:1\u20135.","journal-title":"Cancer Res"},{"key":"3193_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","volume":"163","author":"F Mascia","year":"2003","unstructured":"Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol. 2003;163:303\u201312. https:\/\/doi.org\/10.1016\/S0002-9440(10)63654-1.","journal-title":"Am J Pathol"},{"key":"3193_CR18","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/sj.jid.5700202","volume":"126","author":"L Ritti\u00e9","year":"2006","unstructured":"Ritti\u00e9 L, Varani J, Kang S, et al. Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006;126:732\u20139. https:\/\/doi.org\/10.1038\/sj.jid.5700202.","journal-title":"J Invest Dermatol"},{"key":"3193_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.17816\/dv624831","volume":"27","author":"EV Orlova","year":"2024","unstructured":"Orlova EV, Sekacheva MI, Prokhorova MV, et al. Changes in cytokine profile as a criterion for severity prediction of skin toxicity in cancer patients receiving epidermal growth factor receptor inhibitors. Russ J Skin Venereol Dis. 2024;27:377\u201388. https:\/\/doi.org\/10.17816\/dv624831.","journal-title":"Russ J Skin Venereol Dis"},{"key":"3193_CR20","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/JCI128678","volume":"130","author":"TK Satoh","year":"2020","unstructured":"Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130:1417\u201330. https:\/\/doi.org\/10.1172\/JCI128678.","journal-title":"J Clin Invest"},{"key":"3193_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1848058","author":"D Tougeron","year":"2020","unstructured":"Tougeron D, Emambux S, Favot L, et al. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX). Oncoimmunology. 2020. https:\/\/doi.org\/10.1080\/2162402X.2020.1848058.","journal-title":"Oncoimmunology"},{"key":"3193_CR22","doi-asserted-by":"publisher","first-page":"e55128","DOI":"10.1371\/journal.pone.0055128","volume":"8","author":"H Liu","year":"2013","unstructured":"Liu H, Wu Y, Lv T, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e55128. https:\/\/doi.org\/10.1371\/journal.pone.0055128.","journal-title":"PLoS One"},{"key":"3193_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.804212","author":"Y Li","year":"2022","unstructured":"Li Y, Fu R, Jiang T, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.804212.","journal-title":"Front Oncol"},{"key":"3193_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdin.2023.11.009","volume":"15","author":"S Katz","year":"2024","unstructured":"Katz S, Ciuba D, Ribas A, et al. A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer. JAAD Int. 2024;15:62\u20138. https:\/\/doi.org\/10.1016\/j.jdin.2023.11.009.","journal-title":"JAAD Int"},{"key":"3193_CR25","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/2159-8290.CD-20-1847","volume":"11","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Wainberg ZA, Patel AB, et al. Reducing skin toxicities from EGFR inhibitors with topical BRAF inhibitor therapy. Cancer Discov. 2021;11:2158\u201367. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1847.","journal-title":"Cancer Discov"},{"key":"3193_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.212516","volume":"7","author":"DIG Cubero","year":"2018","unstructured":"Cubero DIG, Abdalla BMZ, Schoueri J, et al. Cutaneous side effects of molecularly targeted therapies for the treatment of solid tumors. Drugs Context. 2018;7:1\u201311. https:\/\/doi.org\/10.7573\/dic.212516.","journal-title":"Drugs Context"},{"key":"3193_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:1351\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.21.7828.","journal-title":"J Clin Oncol"},{"key":"3193_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines\u2606. Ann Oncol. 2021;32:157\u201370. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005.","journal-title":"Ann Oncol"},{"key":"3193_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142526","volume":"16","author":"R Ladwa","year":"2024","unstructured":"Ladwa R, Fogarty G, Chen P, et al. Management of skin toxicities in cancer treatment: an Australian\/New Zealand perspective. Cancers (Basel). 2024;16:2526. https:\/\/doi.org\/10.3390\/cancers16142526.","journal-title":"Cancers (Basel)"},{"key":"3193_CR30","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ad.2019.12.006","volume":"111","author":"FJ Navarro-Trivi\u00f1o","year":"2020","unstructured":"Navarro-Trivi\u00f1o FJ, P\u00e9rez-L\u00f3pez I, Ruiz-Villaverde R. Doxiciclina, \u00bfantibi\u00f3tico o antiinflamatorio? Usos m\u00e1s frecuentes En dermatolog\u00eda. Actas Dermosifiliogr. 2020;111:561\u20136. https:\/\/doi.org\/10.1016\/j.ad.2019.12.006.","journal-title":"Actas Dermosifiliogr"},{"key":"3193_CR31","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/cells10051219","volume":"10","author":"Y Teng","year":"2021","unstructured":"Teng Y, Fan Y, Ma J, et al. The PI3K\/Akt pathway: emerging roles in skin homeostasis and a group of non-malignant skin disorders. Cells. 2021;10:1219. https:\/\/doi.org\/10.3390\/cells10051219.","journal-title":"Cells"},{"key":"3193_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","volume":"1851","author":"PT Hawkins","year":"2015","unstructured":"Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2015;1851:882\u201397. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.006.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"key":"3193_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan SM, Wymann MP, Lucas CL. The role of PI3K\u03b3 in the immune system: new insights and translational implications. Nat Rev Immunol. 2022;22:687\u2013700. https:\/\/doi.org\/10.1038\/s41577-022-00701-8.","journal-title":"Nat Rev Immunol"},{"key":"3193_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.665647","author":"L Mercurio","year":"2021","unstructured":"Mercurio L, Albanesi C, Madonna S. Recent updates on the involvement of PI3K\/AKT\/mTOR molecular cascade in the pathogenesis of hyperproliferative skin disorders. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.665647.","journal-title":"Front Med (Lausanne)"},{"key":"3193_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","volume":"183","author":"DG Wang","year":"2020","unstructured":"Wang DG, Barrios DM, Blinder VS, et al. Dermatologic adverse events related to the PI3K\u03b1 inhibitor Alpelisib (BYL719) in patients with breast cancer. Breast Cancer Res Treat. 2020;183:227\u201337. https:\/\/doi.org\/10.1007\/s10549-020-05726-y.","journal-title":"Breast Cancer Res Treat"},{"key":"3193_CR36","volume-title":"StatPearls","author":"UKR Ismail","year":"2023","unstructured":"Ismail UKR. Taxane Toxicity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023."},{"key":"3193_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3349\/ymj.2007.48.1.124","volume":"48","author":"MR Roh","year":"2007","unstructured":"Roh MR, Cho JY, Lew W. Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. Yonsei Med J. 2007;48:124. https:\/\/doi.org\/10.3349\/ymj.2007.48.1.124.","journal-title":"Yonsei Med J"},{"key":"3193_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15578","author":"RV Narayan","year":"2022","unstructured":"Narayan RV, Subburaj K, Mahajan R. Docetaxel induced hemorrhagic onycholysis. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15578.","journal-title":"Dermatol Ther"},{"key":"3193_CR39","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3109\/0284186X.2011.636755","volume":"51","author":"A Stravodimou","year":"2012","unstructured":"Stravodimou A, Voutsadakis IA. Hand and foot syndrome associated with docetaxel treatment. Acta Oncol (Madr). 2012;51:554\u20136. https:\/\/doi.org\/10.3109\/0284186X.2011.636755.","journal-title":"Acta Oncol (Madr)"},{"key":"3193_CR40","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","volume":"23","author":"F Scott\u00e9","year":"2005","unstructured":"Scott\u00e9 F, Tourani J-M, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23:4424\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.15.651.","journal-title":"J Clin Oncol"},{"key":"3193_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10549-017-4268-7","volume":"164","author":"J-Y Kim","year":"2017","unstructured":"Kim J-Y, Ok ON, Seo J, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant\/adjuvant docetaxel chemotherapy. Breast Cancer Res Treat. 2017;164:617\u201325. https:\/\/doi.org\/10.1007\/s10549-017-4268-7.","journal-title":"Breast Cancer Res Treat"},{"key":"3193_CR42","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","volume":"15","author":"V Nikolaou","year":"2016","unstructured":"Nikolaou V, Syrigos K, Saif MW. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15:1625\u201333. https:\/\/doi.org\/10.1080\/14740338.2016.1238067.","journal-title":"Expert Opin Drug Saf"},{"key":"3193_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14740338.2011.546342","volume":"10","author":"MW Saif","year":"2011","unstructured":"Saif MW. Capecitabine and hand\u2013foot syndrome. Expert Opin Drug Saf. 2011;10:159\u201369. https:\/\/doi.org\/10.1517\/14740338.2011.546342.","journal-title":"Expert Opin Drug Saf"},{"key":"3193_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1749-6632.1988.tb18798.x","volume":"548","author":"PM Schwartz","year":"1988","unstructured":"Schwartz PM, Reuveni H, Milstone LM. Local and systemic implications of thymidine catabolism by human keratinocytes a. Ann N Y Acad Sci. 1988;548:115\u201324. https:\/\/doi.org\/10.1111\/j.1749-6632.1988.tb18798.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3193_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00735915","volume":"32","author":"H Eda","year":"1993","unstructured":"Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridine. Cancer Chemother Pharmacol. 1993;32:333\u20138. https:\/\/doi.org\/10.1007\/BF00735915.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3193_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40801-018-0138-9","volume":"5","author":"MWH van Beek","year":"2018","unstructured":"van Beek MWH, Roukens M, Jacobs WCH, et al. Real-world adverse effects of capecitabine toxicity in an elderly population. Drugs Real World Outcomes. 2018;5:161\u20137. https:\/\/doi.org\/10.1007\/s40801-018-0138-9.","journal-title":"Drugs Real World Outcomes"},{"key":"3193_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2129-z","author":"LT Macedo","year":"2014","unstructured":"Macedo LT, Lima JPN, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand\u2013foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014. https:\/\/doi.org\/10.1007\/s00520-014-2129-z.","journal-title":"Support Care Cancer"},{"key":"3193_CR48","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S, et al. Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol. 2024;42:1821\u20139. https:\/\/doi.org\/10.1200\/JCO.23.01730.","journal-title":"J Clin Oncol"},{"key":"3193_CR49","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00520-014-2465-z","volume":"23","author":"KL Meadows","year":"2015","unstructured":"Meadows KL, Rushing C, Honeycutt W, et al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer. 2015;23:1311\u20139. https:\/\/doi.org\/10.1007\/s00520-014-2465-z.","journal-title":"Support Care Cancer"},{"key":"3193_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052707","volume":"23","author":"R Lombardi","year":"2022","unstructured":"Lombardi R, Piciotti R, Dongiovanni P, et al. PD-1\/PD-L1 immuno-mediated therapy in NAFLD: advantages and obstacles in the treatment of advanced disease. Int J Mol Sci. 2022;23:2707. https:\/\/doi.org\/10.3390\/ijms23052707.","journal-title":"Int J Mol Sci"},{"key":"3193_CR51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","volume":"28","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254\u201363. https:\/\/doi.org\/10.1097\/CCO.0000000000000290.","journal-title":"Curr Opin Oncol"},{"key":"3193_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","volume":"25","author":"A Muntyanu","year":"2021","unstructured":"Muntyanu A, Netchiporouk E, Gerstein W, et al. Cutaneous immune-Related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management. J Cutan Med Surg. 2021;25:59\u201376. https:\/\/doi.org\/10.1177\/1203475420943260.","journal-title":"J Cutan Med Surg"},{"key":"3193_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4103\/ijd.ijd_123_23","volume":"69","author":"E Tolino","year":"2024","unstructured":"Tolino E, Proietti I, Skroza N, et al. Atopic dermatitis onset in a melanoma patient under pembrolizumab therapy: a case of successful treatment with dupilumab. Indian J Dermatol. 2024;69:268\u20139. https:\/\/doi.org\/10.4103\/ijd.ijd_123_23.","journal-title":"Indian J Dermatol"},{"key":"3193_CR54","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.34004","volume":"128","author":"AB Patel","year":"2022","unstructured":"Patel AB, Farooq S, Welborn M, et al. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti\u2010PD1 combination immunotherapy: incidence, management, and clinical benefit. Cancer. 2022;128:975\u201383. https:\/\/doi.org\/10.1002\/cncr.34004.","journal-title":"Cancer"},{"key":"3193_CR55","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126. https:\/\/doi.org\/10.1200\/JCO.21.01440.","journal-title":"J Clin Oncol"},{"key":"3193_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.14740\/wjon2612","volume":"16","author":"S Shambhavi","year":"2025","unstructured":"Shambhavi S, DiVanna M, Sharma S, et al. Demographic variations in immune checkpoint inhibitor adverse events: a real-world study. World J Oncol. 2025;16:439\u201345. https:\/\/doi.org\/10.14740\/wjon2612.","journal-title":"World J Oncol"},{"key":"3193_CR57","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1200\/JCO.19.00489","volume":"37","author":"C Menzer","year":"2019","unstructured":"Menzer C, Menzies AM, Carlino MS, et al. Targeted therapy in advanced melanoma with rare BRAF mutations. J Clin Oncol. 2019;37:3142\u201351. https:\/\/doi.org\/10.1200\/JCO.19.00489.","journal-title":"J Clin Oncol"},{"key":"3193_CR58","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436\u201344. https:\/\/doi.org\/10.1016\/S1470-2045(14)70051-8.","journal-title":"Lancet Oncol"},{"key":"3193_CR59","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5114\/pdia.2015.48045","volume":"1","author":"E Nowara","year":"2016","unstructured":"Nowara E, Huszno J, Slomian G, Nieckula J. Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib. Adv Dermatol Allergol. 2016;1:52\u20136. https:\/\/doi.org\/10.5114\/pdia.2015.48045.","journal-title":"Adv Dermatol Allergol"},{"key":"3193_CR60","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1200\/jco.2013.31.15_suppl.9013","volume":"31","author":"A Hauschild","year":"2013","unstructured":"Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol. 2013;31:9013\u20139013. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.9013.","journal-title":"J Clin Oncol"},{"key":"3193_CR61","doi-asserted-by":"publisher","first-page":"12348","DOI":"10.1038\/ncomms12348","volume":"7","author":"H Escuin-Ordinas","year":"2016","unstructured":"Escuin-Ordinas H, Li S, Xie MW, et al. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun. 2016;7:12348. https:\/\/doi.org\/10.1038\/ncomms12348.","journal-title":"Nat Commun"},{"key":"3193_CR62","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"key":"3193_CR63","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","volume":"151","author":"G Carlos","year":"2015","unstructured":"Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103. https:\/\/doi.org\/10.1001\/jamadermatol.2015.1745.","journal-title":"JAMA Dermatol"},{"key":"3193_CR64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","volume":"48","author":"C Gomez-Fernandez","year":"2012","unstructured":"Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer. 2012;48:340\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.028.","journal-title":"Eur J Cancer"},{"key":"3193_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010068","volume":"16","author":"ST Sonis","year":"2023","unstructured":"Sonis ST, Villa A. A new hypothesis describing the pathogenesis of oral mucosal injury associated with the mammalian target of rapamycin (mTOR) inhibitors. Cancers (Basel). 2023;16:68. https:\/\/doi.org\/10.3390\/cancers16010068.","journal-title":"Cancers (Basel)"},{"key":"3193_CR66","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18:654\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2.","journal-title":"Lancet Oncol"},{"key":"3193_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/j.seminoncol.2023.01.001","volume":"50","author":"KJ Ruddy","year":"2023","unstructured":"Ruddy KJ, Zahrieh D, He J, et al. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023;50:7\u201310. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.01.001.","journal-title":"Semin Oncol"},{"key":"3193_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.630942.","journal-title":"Front Cell Dev Biol"},{"key":"3193_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103696","volume":"174","author":"S Nocco","year":"2022","unstructured":"Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic toxicities: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;174:103696. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103696.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3193_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14190","author":"A Pileri","year":"2020","unstructured":"Pileri A, Guglielmo A, Agostinelli C, et al. Cutaneous adverse-events in patients treated with Ibrutinib. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.14190.","journal-title":"Dermatol Ther"},{"key":"3193_CR71","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","volume":"6","author":"CS Tam","year":"2022","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6:1296\u2013308. https:\/\/doi.org\/10.1182\/bloodadvances.2021005621.","journal-title":"Blood Adv"},{"key":"3193_CR72","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jaad.2019.12.031","volume":"88","author":"S Singer","year":"2023","unstructured":"Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor\u2013induced dermatologic adverse events. J Am Acad Dermatol. 2023;88:1271\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.031.","journal-title":"J Am Acad Dermatol"},{"key":"3193_CR73","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619:707\u201315. https:\/\/doi.org\/10.1038\/s41586-023-06243-w.","journal-title":"Nature"},{"key":"3193_CR74","doi-asserted-by":"publisher","first-page":"1035.e1","DOI":"10.1016\/j.jtct.2024.06.024","volume":"30","author":"R Storgard","year":"2024","unstructured":"Storgard R, Dusza S, Shouval R, et al. Dermatologic adverse events associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA reporting system. Transplant Cell Ther. 2024;30:1035.e1-1035.e7. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.024.","journal-title":"Transplant Cell Ther"},{"key":"3193_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.950923.","journal-title":"Front Pharmacol"},{"key":"3193_CR76","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1001\/jamadermatol.2020.0636","volume":"156","author":"Y Hu","year":"2020","unstructured":"Hu Y, Zheng W, Qiao J, et al. Bullous and exanthematous lesions associated with chimeric antigen receptor T-Cell therapy in a patient with diffuse large B-Cell lymphoma. JAMA Dermatol. 2020;156:1026. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0636.","journal-title":"JAMA Dermatol"},{"key":"3193_CR77","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","volume":"98","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu L, Guo T, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98:1721\u201332. https:\/\/doi.org\/10.1007\/s00277-019-03685-z.","journal-title":"Ann Hematol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03193-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03193-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03193-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:50:10Z","timestamp":1769485810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03193-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03193-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}